ArticleJAMA network open2022

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases.

Siddharth Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.